Market revenue in 2023 | USD 20.0 million |
Market revenue in 2030 | USD 26.3 million |
Growth rate | 4% (CAGR from 2023 to 2030) |
Largest segment | Controls |
Fastest growing segment | Calibrators |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Controls, Calibrators |
Key market players worldwide | Siemens Healthineers AG ADR, Abbott Laboratories, Bio-Rad Laboratories Inc, Danaher Corp, Roche Holding AG ADR, Sysmex Corp, QuidelOrtho Corp, Thermo Fisher Scientific Inc, BD, Merck KGaA, Qiagen NV, Hologic Inc, Bio-Techne Corp, Randox, Helena Laboratories, Seracare Life Sciences, Fortress Diagnostics, Microbiologics, TRINA BIOREACTIVES, Cone Bioproducts, Biorex Food Diagnostics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to in vitro diagnostics quality control market will help companies and investors design strategic landscapes.
Controls was the largest segment with a revenue share of 48.5% in 2023. Horizon Databook has segmented the Australia in vitro diagnostics quality control market based on controls, calibrators covering the revenue growth of each sub-segment from 2018 to 2030.
The prevalence of diseases like diabetes and cardiovascular disorders is growing in Australia. For instance, according to the Baker Heart and Diabetes Institute, over 500,000 individuals in Australia are suffering from atrial fibrillation, and its prevalence can largely be attributed to diabetes. In addition, the prevalence of cancer is growing in the country.
According to Cancer Australia, more than 162,000 cancer cases were estimated to be diagnosed in 2022, and this number is expected to rise to 239,770 by 2030. Furthermore, in 2022, over 1.3 million people in the country had diabetes.
In addition, one in four people living with diabetes remains undiagnosed. The high burden of diseases in the country is expected to create growth opportunities for IVD tests and quality control. In Australia, clinical laboratory tests have major economic value.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia in vitro diagnostics quality control market , including forecasts for subscribers. This country databook contains high-level insights into Australia in vitro diagnostics quality control market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account